IL1B and stroke disorder: The majority of preclinical studies elected to administer MSCs, CM and exosomes during the acute phase of stroke (≤ 48 h) where secondary damage is mediated by reactive oxygen species, migration of immune cells to the ischaemic brain and production of pro-inflammatory cytokines such as IL-1.149 As a number of studies have demonstrated immunomodulatory and neuroprotective effects of the MSC secretome, such a time point may hold therapeutic potential.